$360 Million is the total value of MPM BioImpact LLC's 37 reported holdings in Q2 2022. The portfolio turnover from Q1 2022 to Q2 2022 was 21.6% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CGEM | Cullinan Oncology, Inc. | $98,051,000 | +22.4% | 7,648,268 | 0.0% | 27.24% | +26.7% | |
| ITOS | iTeos Therapeutics, Inc. | $35,966,000 | -36.0% | 1,745,943 | 0.0% | 9.99% | -33.7% | |
| RPTX | Repare Therapeutics, Inc. | $22,941,000 | -1.8% | 1,639,849 | 0.0% | 6.37% | +1.7% | |
| MRUS | Merus N.V. | $20,817,000 | -14.4% | 919,482 | 0.0% | 5.78% | -11.4% | |
| NTLA | Buy | Intellia Therapeutics, Inc. | $15,497,000 | +33.8% | 299,409 | +87.8% | 4.30% | +38.5% |
| IOVA | New | Iovance Biotherapeutics Inc Com | $13,248,000 | – | 1,200,000 | +100.0% | 3.68% | – |
| GERN | Buy | Geron Corporation | $13,074,000 | +56.3% | 8,434,991 | +37.2% | 3.63% | +61.9% |
| INBX | New | Inhibrx, Inc. | $11,615,000 | – | 1,023,325 | +100.0% | 3.23% | – |
| TCRR | TCR2 Therapeutics, Inc. | $9,776,000 | +5.1% | 3,370,982 | 0.0% | 2.72% | +8.8% | |
| HOWL | Werewolf Therapeutics, Inc. | $9,767,000 | -7.0% | 2,388,011 | 0.0% | 2.71% | -3.8% | |
| CYTK | Sell | Cytokinetics Inc. | $7,632,000 | -7.5% | 194,246 | -13.4% | 2.12% | -4.3% |
| CRNX | Crinetics Pharmaceuticals Inc. | $6,839,000 | -15.0% | 366,676 | 0.0% | 1.90% | -12.0% | |
| BCRX | Biocryst Pharmaceuticals Inc. | $6,762,000 | -34.9% | 639,089 | 0.0% | 1.88% | -32.7% | |
| TVTX | Travere Therapeutics Inc. | $6,735,000 | -6.0% | 277,950 | 0.0% | 1.87% | -2.7% | |
| YMAB | YmAbs Therapeutics, Inc. | $6,713,000 | +27.4% | 443,702 | 0.0% | 1.86% | +31.8% | |
| HRMY | Harmony Biosciences Hldgs Inc. | $6,707,000 | +0.3% | 137,517 | 0.0% | 1.86% | +3.8% | |
| HARP | Harpoon Therapeutics, Inc. | $6,106,000 | -61.6% | 3,196,707 | 0.0% | 1.70% | -60.2% | |
| MIRM | Mirum Pharmaceuticals Inc. | $5,615,000 | -11.6% | 288,531 | 0.0% | 1.56% | -8.5% | |
| ARQT | Arcutis Biotherapeutics inc | $5,509,000 | +10.6% | 258,500 | 0.0% | 1.53% | +14.5% | |
| RETA | Reata Pharmaceuticals inc-a | $5,470,000 | -7.2% | 180,000 | 0.0% | 1.52% | -4.0% | |
| FOLD | Amicus Therapeutics Inc. | $5,323,000 | +13.4% | 495,603 | 0.0% | 1.48% | +17.5% | |
| EPZM | Epizyme, Inc. | $5,035,000 | +27.8% | 3,425,202 | 0.0% | 1.40% | +32.4% | |
| GTHX | G1 Therapeutics, Inc. | $4,233,000 | -35.0% | 856,798 | 0.0% | 1.18% | -32.7% | |
| VSTM | Verastem, Inc. | $3,764,000 | -17.7% | 3,244,650 | 0.0% | 1.05% | -14.8% | |
| MDGL | New | Madrigal Pharmaceuticals inc | $3,221,000 | – | 45,000 | +100.0% | 0.90% | – |
| INZY | Buy | Inozyme Pharma Inc. | $3,172,000 | +163.0% | 664,980 | +125.4% | 0.88% | +171.9% |
| ONCR | Oncorus, Inc. | $2,995,000 | -29.2% | 2,377,031 | 0.0% | 0.83% | -26.8% | |
| RVMD | Revolution Medicines, Inc. | $2,846,000 | -23.6% | 146,041 | 0.0% | 0.79% | -20.9% | |
| ADCT | ADC Therapeutics, Inc. | $2,658,000 | -45.9% | 334,384 | 0.0% | 0.74% | -44.0% | |
| KRTX | Karuna Therapeutics inc | $2,530,000 | -0.2% | 20,000 | 0.0% | 0.70% | +3.2% | |
| PRVB | New | Provention Bio Inc | $2,370,000 | – | 592,435 | +100.0% | 0.66% | – |
| EPIX | ESSA Pharma, Inc. | $2,082,000 | -49.0% | 660,892 | 0.0% | 0.58% | -47.3% | |
| PHAT | Phathom Pharmaceuticals inc | $1,632,000 | -38.0% | 193,326 | 0.0% | 0.45% | -35.8% | |
| NEO | Neogenomics Inc. | $1,105,000 | -32.9% | 135,573 | 0.0% | 0.31% | -30.5% | |
| AVDL | Avadel Pharmaceuticals Plcadr | $1,006,000 | -64.3% | 412,363 | 0.0% | 0.28% | -63.1% | |
| AVRO | AVROBIO, Inc. | $596,000 | -30.3% | 647,918 | 0.0% | 0.17% | -27.5% | |
| BDTX | Black Diamond Therapeutics, Inc. | $590,000 | -11.1% | 239,888 | 0.0% | 0.16% | -7.9% | |
| ACAD | Exit | Acadia Pharmaceuticals Inc | $0 | – | -151,750 | -100.0% | -0.99% | – |
| RLMD | Exit | Relmada Therapeutics inc | $0 | – | -138,000 | -100.0% | -1.00% | – |
| AXSM | Exit | Axsome Therapeutics Inc. | $0 | – | -99,834 | -100.0% | -1.11% | – |
| TPTX | Exit | Turning Point Therapeutics, Inc. | $0 | – | -351,350 | -100.0% | -2.53% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-08-11
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Harpoon Therapeutics, Inc. | 15 | Q2 2023 | 27.6% |
| Repare Therapeutics, Inc. | 14 | Q3 2023 | 19.7% |
| TCR2 Therapeutics, Inc. | 14 | Q1 2023 | 18.0% |
| iTeos Therapeutics, Inc. | 13 | Q3 2023 | 15.7% |
| G1 Therapeutics, Inc. | 13 | Q4 2022 | 13.3% |
| Y Mabs Therapeutics, Inc. | 12 | Q3 2022 | 5.4% |
| Cullinan Oncology, Inc. | 11 | Q3 2023 | 41.4% |
| Epizyme, Inc. | 11 | Q2 2022 | 22.1% |
| Oncorus, Inc. | 11 | Q2 2023 | 13.3% |
| Intellia Therapeutics, Inc. | 10 | Q3 2023 | 5.5% |
View MPM BioImpact LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-13 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| SC 13D/A | 2023-08-01 |
| SC 13D | 2023-06-12 |
| 4 | 2023-06-05 |
| 13F-HR | 2023-05-12 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-11 |
View MPM BioImpact LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.